Oxidized DJ-1 as a possible biomarker of Parkinson's disease

Journal of Clinical Biochemistry and Nutrition

Volumn 54, Issue 3, 2014, Pages 138-144

  Saito, Yoshiro ^a  

^a DOSHISHA UNIVERSITY   (Japan)

Author keywords

Cysteine; DJ 1; Oxidative stress; Parkinson's disease; Sulfonic acid

Indexed keywords

ANTIBODY; ANTIOXIDANT; BIOLOGICAL MARKER; CYSTEINE; DJ 1 PROTEIN;

ANTIOXIDANT ACTIVITY; CELL FUNCTION; CELL PROTECTION; GENE CONTROL; GENE EXPRESSION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW;

EID: 84900397759     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.13-108     Document Type: Review

References (71)

1. Bonifati V. Autosomal recessive parkinsonism. Parkinsonism Relat Disord 2012; 18: S4-S6.
2. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev 2013; 2013: 683920.
3. Kahle PJ, Waak J, Gasser T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Rad Biol Med 2009; 47: 1354-1361.
4. Kinumi T, Kimata J, Taira T, Ariga H, Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 317: 722-728. (Pubitemid 38481432)
5. Wilson MA. The role of cysteine oxidation in DJ-1 function and dysfunction. Antioxid Redox Signal 2011; 15: 111-122.
6. Saito Y, Hamakubo T, Yoshida Y, et al. Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. Neurosci Lett 2009; 465: 1-5.
7. Akazawa YO, Saito Y, Hamakubo T, et al. Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals. Neurosci Lett 2010; 483: 201-205.
8. Miyama A, Saito Y, Yamanaka K, Hayashi K, Hamakubo T, Noguchi N. Oxidation of DJ-1 induced by 6-hydroxydopamine decreasing intracellular glutathione. PLoS One 2011; 6: e27883.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
10. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-272. (Pubitemid 26085575)
11. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134. (Pubitemid 39362633)
12. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008; 21: 172-188. (Pubitemid 351219718)
13. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinson Dis 2013; 3: 461-491.
14. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002; 3: 932-942.
15. Maker HS, Weiss C, Silides DJ, Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 1981; 36: 589-593. (Pubitemid 11190630)
16. Guzman JN, Sanchez-Padilla J, Wokosin D, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010; 468: 696-700.
17. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992; 42: 1328-1335.
18. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992; 32 (Suppl): S94-S100.
19. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982; 33: 305-310. (Pubitemid 13119539)
20. Bellinger FP, Bellinger MT, Seale LA, et al. Glutathione peroxidase 4 is associated with neuromelanin in substantia nigra and dystrophic axons in putamen of Parkinson's brain. Mol Neurodegener 2011; 6: 8.
21. Lesage S, Brice A. Role of mendelian genes in "sporadic" Parkinson's disease. Parkinsonism Relat Disord 2012; 18: S66-S70.
22. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047. (Pubitemid 27443610)
23. Bonifati V, Rizzu P, van Baren MJ. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259. (Pubitemid 36131051)
24. Nagakubo D, Taira T, Kitaura H, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997; 231: 509-513. (Pubitemid 27214343)
25. Okada M, Matsumoto K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice. Biol Pharm Bull 2002; 25: 853-856. (Pubitemid 40022111)
26. Mitsumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 2001; 35: 301-310. (Pubitemid 32734231)
27. Honbou K, Suzuki NN, Horiuchi M, et al. The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J Biol Chem 2003; 278: 31380-31384. (Pubitemid 36994658)
28. Huai Q, Sun Y, Wang H, et al. Crystal structure of DJ-1/RS and implication on familial Parkinson's disease. FEBS Lett 2003; 549: 171-175. (Pubitemid 36959865)
29. Wilson MA, Ringe D, Petsko GA. The atomic resolution crystal structure of the YajL (ThiJ) protein from Escherichia coli: a close prokaryotic homologue of the Parkinsonism-associated protein DJ-1. J Mol Biol 2005; 353: 678-691. (Pubitemid 41414740)
30. Mitsugi H, Niki T, Takahashi-Niki K, et al. Identification of the recognition sequence and target proteins for DJ-1 protease. FEBS Lett 2013; 587: 2493-2499.
31. Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol 2006; 356: 1036-1048. (Pubitemid 43145955)
32. Le HT, Gautier V, Kthiri F, et al. YajL, prokaryotic homolog of parkinsonism-associated protein DJ-1, functions as a covalent chaperone for thiol proteome. J Biol Chem 2012; 287: 5861-5870.
33. Knobbe CB, Revett TJ, Bai Y, et al. Choice of biological source material supersedes oxidative stress in its influence on DJ-1 in vivo interactions with Hsp90. J Proteome Res 2011; 10: 4388-4404.
34. Lee JY, Song J, Kwon K, et al. Human DJ-1 and its homologs are novel glyoxalases. Hum Mol Gen 2012; 21: 3215-3225.
35. Witt AC, Lakshminarasimhan M, Remington BC, Hasim S, Pozharski E, Wilson MA. Cysteine pKa depression by a protonated glutamic acid in human DJ-1. Biochem 2008; 47: 7430-7440. (Pubitemid 351991022)
36. Blackinton J, Lakshminarasimhan M, Thomas KJ, et al. Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem 2009; 284: 6476-6485.
37. Waak J, Weber SS, Görner K, et al. Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signalregulating kinase 1. J Biol Chem 2009; 284: 14245-14257.
38. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004; 5: 213-218. (Pubitemid 38401204)
39. Zhou W, Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 2005; 280: 43150-43158. (Pubitemid 43049281)
40. Im JY, Lee KW, Woo JM, Junn E, Mouradian MM. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Gen 2012; 21: 3013-3024.
41. Kato I, Maita H, Takahashi-Niki K, et al. Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. Mol Cell Biol 2013; 33: 340-359.
42. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274. (Pubitemid 46962095)
43. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133: 403-414. (Pubitemid 351622014)
44. Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005; 7: 263-273. (Pubitemid 40568685)
45. Kim YC, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H. Oxidation of DJ-1-dependent cell transformation through direct binding of DJ-1 to PTEN. Int J Oncol 2009; 35: 1331-1341.
46. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Nat Acad Sci U S A 2005; 102: 9691-9696. (Pubitemid 40981742)
47. Karunakaran S, Diwakar L, Saeed U, et al. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J 2007; 21: 2226-2236. (Pubitemid 47026457)
48. Klawitter J, Klawitter J, Agardi E, et al. Association of DJ-1/PTEN/AKT-and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy. Cardiovasc Res 2013; 97: 66-76.
49. Wang Z, Liu J, Chen S, et al. DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Ann Neurol 2011; 70: 591-599.
50. Maita C, Maita H, Iguchi-Ariga SM, Ariga H. Monomer DJ-1 and its N-terminal sequence are necessary for mitochondrial localization of DJ-1 mutants. PLoS One 2013; 8: e54087.
51. Hayashi T, Ishimori C, Takahashi-Niki K, et al. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Biophys Res Commun 2009; 390: 667-672.
52. Zhong N, Kim CY, Rizzu P, et al. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem 2006; 281: 20940-20948. (Pubitemid 44115435)
53. Ishikawa S, Taira T, Niki T, et al. Oxidative status of DJ-1-dependent activation of dopamine synthesis through interaction of tyrosine hydroxylase and 4-dihydroxy-L-phenylalanine (L-DOPA) decarboxylase with DJ-1. J Biol Chem 2009; 284: 28832-28844.
54. Jones R. Biomarkers: casting the net wide. Nature 2010; 466: S11-S12.
55. Booij J, Tissingh G, Winogrodzka A, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71. (Pubitemid 27122444)
56. Oakley AE, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007; 68: 1820-1825. (Pubitemid 46791395)
57. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 189-194. (Pubitemid 29326950)
58. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20: 419-425. (Pubitemid 44933318)
59. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010; 4: 683-699.
60. Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nature Rev Neurol 2013; 9: 131-140.
61. Schapira AH. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol 2013; 26: 395-400.
62. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629-635.
63. Yanagida T, Tsushima J, Kitamura Y, et al. Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury. Oxid Med Cell Longev 2009; 2: 36-42.
64. Maita C, Tsuji S, Yabe I, et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 2008; 431: 86-89.
65. Waragai M, Nakai M, Wei J, et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 2007; 425: 18-22. (Pubitemid 47410359)
66. Shi M, Zabetian CP, Hancock AM, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosc Lett 2010; 480: 78-82.
67. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713-726.
68. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69: 570-580.
69. Salvesen L, Bech S, Lokkegaard A, et al. The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes. Parkinsonism Relat Disord 2012; 18: 899-901.
70. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746. (Pubitemid 47058377)
71. Lin X, Cook TJ, Zabetian CP, et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep 2012; 2: 954.